6 unknown, 4 completed, 3 recruiting, 2 not yet recruiting. 11 Phase 2, 3 Not applicable, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Unknown 5, Completed 3, Recruiting 2, Not yet recruiting 1 |
| Not applicable | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Oxaliplatin: new trials by email Literature Review of Oxaliplatin trials Research Report on Oxaliplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor | Phase 3 | Not yet recruiting | Guangdong Provincial People's Hospital | 148 | 2027-01-01 | 2026-07-07 |
| Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer Oxaliplatin plus S-1, Docetaxel plus S-1 - Gastric Cancer (GC), Adjuvant Chemotherapy | Phase 3 | Recruiting | Ruijin Hospital | 387 | 2025-12-15 | 2026-01-26 |
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab - Nanoliposomal Irinotecan, Cadonilimab | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-04-17 | 2024-12-24 |
| XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine - Tislelizumab, Bevacizumab | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 52 | 2023-07-07 | 2023-08-01 |
| Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors TACE, Tislelizumab, Lenvatinib - Hepatocellular Carcinoma, Lenvatinib | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 35 | 2023-07-01 | 2025-02-11 |
| Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer Tislelizumab - MSI-H Colorectal Cancer, Tislelizumab | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 25 | 2023-06-01 | 2023-05-09 |
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients Acupuncture, Sham-acupuncture - Colorectal Cancer, Oxaliplatin | Not applicable | Unknown | Hong Kong Baptist University | 150 | 2023-05-01 | 2023-04-05 |
| A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis Experimental: FOLFOXIRI and Lateral lymph node dissection, Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection - Lymph Node Metastasis, Cancer of Rectum and Anus | Not applicable | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 180 | 2022-10-01 | 2026-04-06 |
| SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma sintilimab, Trastuzumab, S-1 plus oxaliplatin - HER2-positive, Locally Advanced Solid Tumor | Phase 2 | Unknown | Aiping Zhou | 44 | 2022-04-01 | 2022-04-06 |
| Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery Hepatic arterial infusion chemotherapy, Folfox Protocol, Donafenib - Carcinoma, Carcinoma, Hepatocellular | Phase 2 | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2021-12-27 | 2026-06-30 |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab - Hepatocellular Carcinoma, Bevacizumab | Phase 2 | Unknown | Sun Yat-sen University | 30 | 2021-01-01 | 2020-11-13 |
| Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively, Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices - Hyperthermia, Colorectal Neoplasms | Not applicable | Terminated | Ciusss de L'Est de l'Île de Montréal | 9 | 2019-05-08 | 2021-10-08 |
| FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma Irinotecan, 5-FU, Leucovorin - Stomach Neoplasms, Gastrointestinal Neoplasms | Phase 2 / Phase 3 | Unknown | Blokhin's Russian Cancer Research Center | 538 | 2019-01-29 | 2021-04-13 |
| Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer S-1 (TS-1) and Oxaliplatin (Oxalitin) - Elderly, S-1 | Phase 2 | Unknown | Soonchunhyang University Hospital | 36 | 2009-08-01 | 2009-08-18 |
| A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer Gemcitabine and Oxaliplatin - Advanced Biliary Tract Adenocarcinoma, Gemcitabine | Phase 2 | Completed | Soonchunhyang University Hospital | 40 | 2006-09-01 | 2014-05-20 |
| CCRT for Esophageal Cancer. Paclitaxel, Oxaliplatin, Radiotherapy - Esophageal Cancer, Concurrent Chemoradiotherapy | Phase 2 | Completed | Hangzhou Cancer Hospital | 34 | 2005-01-01 | 2016-02-17 |
Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Stomach Neoplasms (3) · Carcinoma (2) · Gastrointestinal Neoplasms (2) · Liver Neoplasms (2) · Digestive System Neoplasms (1) · Esophageal Neoplasms (1) · Hyperthermia (1) · Intestinal Neoplasms (1) · Lymphatic Metastasis (1) · Neoplasms (1) · Neurotoxicity Syndromes (1) · Rectal Diseases (1) · Rectal Neoplasms (1)
Digestive System Diseases (11) · Neoplasms by Site (11) · Digestive System Neoplasms (10) · Neoplasms (10) · Gastrointestinal Diseases (8) · Gastrointestinal Neoplasms (6) · Intestinal Diseases (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Adenocarcinoma (3) · Colonic Diseases (3) · Intestinal Neoplasms (3) · Liver Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Rectal Diseases (3)
Oxaliplatin (9) · S 1 (combination) (3) · Capecitabine (2) · Docetaxel (2) · Fluorouracil (2) · Leucovorin (2) · sintilimab (2) · tislelizumab (2) · Acupuncture Therapy (1) · Bevacizumab (1) · Control Groups (1) · Folfox protocol (1) · Gemcitabine (1) · Irinotecan (1) · Paclitaxel (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Soonchunhyang University Hospital (2) · Aiping Zhou (1) · Blokhin's Russian Cancer Research Center (1) · Ciusss de L'Est de l'Île de Montréal (1) · Guangdong Provincial People's Hospital (1) · Hangzhou Cancer Hospital (1) · Hong Kong Baptist University (1) · Ruijin Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Zhengzhou University (1) · Zhejiang Cancer Hospital (1)
China (8) · Canada (1) · Hong Kong (1) · Russia (1) · South Korea (1)
Dae Sik Hong, professor (1) · Fei Gao (1) · Ivan Stilidi, PhD (1) · Kangshun Zhu, Professor (1) · Lei Zhang, PHD (1) · Sang-Cheol Lee, M.D. (1)